Lapatinib, a dual tyrosine kinase inhibitor used for ErbB2-positive breast cancer, inhibits CIP2A, resulting in the inactivation of Akt signaling and increased apoptosis in cancer cells [129]. Here, CIP2A is linked to cancer.